Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor

Gastric Cancer. 2021 Nov;24(6):1374-1375. doi: 10.1007/s10120-021-01246-w. Epub 2021 Sep 5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Benzamides
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Piperazines
  • Stomach Neoplasms*

Substances

  • Benzamides
  • Piperazines
  • Imatinib Mesylate